{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:07:08Z","timestamp":1789020428241,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017642","name":"Spanish National Plan for Scientific and Technical Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tofacitinib is a Janus kinase inhibitor used to treat inflammatory diseases, including rheumatoid arthritis and ulcerative colitis (UC). Previous studies have reported an increased risk of thromboembolic events in patients with rheumatoid arthritis treated with tofacitinib. Therefore, evaluating whether these effects are also present in other inflammatory diseases such as UC is important.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this exploratory study, we evaluated the impact of tofacitinib on platelet function and coagulation profiles in patients with active UC receiving tofacitinib (n=10), compared with patients treated with anti-TNF agents (n=10) and healthy controls (HC; n=10). Patients were assessed at baseline and after 14 weeks of treatment. Platelet aggregation was assessed by lumiaggregometry, while platelet activation was evaluated by flow cytometry through PAC-1 binding and surface expression of CD62P and CD63. Coagulation was assessed by rotational thromboelastometry (ROTEM\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) using extrinsic (EXTEM) and intrinsic (INTEM) pathway activation assays. Longitudinal analyses evaluated the effects of time, treatment, and their interaction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tofacitinib did not significantly affect platelet aggregation or the expression of platelet activation markers compared with either anti-TNF-treated patients or HC. Regarding thrombus dynamics, a significant difference was observed only in the INTEM assay when comparing the tofacitinib and anti-TNF groups, showing longer clot formation times in tofacitinib-treated patients; however, neither group differed from HC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, tofacitinib treatment was not associated with increased platelet aggregation, platelet activation, or enhanced coagulation in patients with UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1941163","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:33:29Z","timestamp":1789018409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib does not affect platelet function or coagulation in patients with ulcerative colitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Fabio","family":"Suarez-Trujillo","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Soleto","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Meij\u00f3n","sequence":"additional","affiliation":[{"name":"Hematology and Hemotherapy Service, Thrombosis and Haemostasis laboratory, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kerguelen","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario de La Paz-IdiPAZ","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Orts","sequence":"additional","affiliation":[{"name":"Anesthesiology Service, Hospital Universitario de La Princesa","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Planas","sequence":"additional","affiliation":[{"name":"Anesthesiology Service, Hospital Universitario de La Princesa","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Acedo","sequence":"additional","affiliation":[{"name":"Hematology Service, Hospital Universitario de La Princesa","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Chac\u00f3n-Calvo","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Garre","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Moreno-Lopez","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Butta","sequence":"additional","affiliation":[{"name":"Coagulopathies and Hemostasis Disorders Group, Hospital Universitario de La Paz-IdiPAZ","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Bald\u00e1n-Mart\u00edn","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Hospital Universitario de La Princesa, Instituto de Investigation Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of disease: Inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8816041","article-title":"Th17 cells in inflammatory bowel disease: Cytokines, plasticity, and therapies","volume":"2021","author":"Zhao","year":"2021","journal-title":"J Immunol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/ibd\/izaf273","article-title":"Janus kinase inhibitors for inflammatory bowel disease: Concise questions and answers on their use in clinical practice","volume":"32","author":"Gisbert","year":"2026","journal-title":"Inflammation Bowel Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf021","article-title":"Janus kinase inhibitors in the management of acute severe ulcerative colitis: A comprehensive review","volume":"19","author":"Gisbert","year":"2025","journal-title":"J Crohns Colitis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: A post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B9","unstructured":"FDA\n          Xeljanz, Xeljanz XR Tofacitinib: Drug safety communication - Due to an increased risk of blood clots and death with higher dose"},{"key":"B10","unstructured":"Tofacitinib (Xeljanz\u25bc): new measures to minimise risk of venous thromboembolism and of serious and fatal infections"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04129.x","article-title":"Platelets in inflammatory bowel disease: Clinical, pathogenic, and therapeutic implications","volume":"99","author":"Danese","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: An analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2025.118","article-title":"Coagulopathy and platelet abnormalities in patients with inflammatory bowel disease","volume":"40","author":"Kim","year":"2025","journal-title":"Korean J Intern Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(03)00289-0","article-title":"Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients","volume":"124","author":"Danese","year":"2003","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.10.1435","article-title":"Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients","volume":"52","author":"Danese","year":"2003","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20896","article-title":"Inflammatory bowel disease: A paradigm for the link between coagulation and inflammation","volume":"15","author":"Yoshida","year":"2009","journal-title":"Inflammation Bowel Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA Registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: Systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflammation Bowel Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001608","article-title":"Effectiveness and safety of tofacitinib for ulcerative colitis: Systematic review and meta-analysis","volume":"56","author":"Taneja","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040557","article-title":"Effect of tofacitinib on hemostasis in patients with ulcerative colitis: A comparative ex vivo study","volume":"18","author":"S\u00e1nchez-S\u00e1nchez","year":"2025","journal-title":"Pharm (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1941163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:33:31Z","timestamp":1789018411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1941163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1941163"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1941163","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1941163"}}